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Background: For patients with multiple sclerosis (MS), previous research identified key disease sequelae as important
cost drivers and suggested that among users of disease-modifying drugs (DMDs) in 2004, DMDs represented 73% of
the total cost of care. More recent studies were limited to incident disease/treatment and/or excluded DMDs from
cost estimates. To support contemporary pharmacoeconomic analyses, the present study was conducted to provide
updated information about MS-related costs and cost drivers including DMDs.
Methods: For each of 2 years, 2006 and 2011, commercially insured, continuously eligible patients with ≥ 1 medical
claim diagnosis of MS were sampled. MS-related charges were based on medical claims with MS diagnosis plus
medical/pharmacy claims for DMDs. 2006 charges were adjusted to 2011 $ using the medical care component of the
consumer price index (CPI). Subgroups of patients using DMDs (interferon [IFN] beta-1a intramuscular or subcutaneous,
IFN beta-1b, glatiramer, natalizumab) in 2011 were identified. By-group differences were tested with bivariate statistics.
Results: Mean (standard deviation [SD]) age of 15,902 sample patients in 2011 was 47.6 (11.8) years, 76% female. Mean
[SD] MS charges ($26,520 [$38,478] overall) were significantly (P < 0.001) higher for patients with common disease
sequelae: malaise/fatigue (n = 2,235; $39,948 [$48,435]), paresthesia (n = 1,566; $33,648 [$45,273]), depression (n = 1,255;
$42,831 [$51,693]), and abnormality of gait (n = 1,196; $48,361 [$55,472]). From 2006 to 2011, CPI-adjusted MS
charges increased by 60%. Among patients treated with a single DMD in 2011, inpatient care was 6% of
charges (range = 4%-8%; P = 0.155); outpatient care was 19% (range = 14%-20% except for natalizumab [29%];
P < 0.001); and DMDs were 75% (range = 67%-81%; P < 0.001).
Conclusions: Common MS sequelae remain important cost drivers. Although MS treatment costs are increasing,
the proportion of MS charges due to DMDs in 2011 is similar to that reported in 2004.Background
Multiple sclerosis (MS) is a chronic, disabling disorder
of the central nervous system that typically presents ini-
tially in early adulthood, with symptoms and disease
progression rates that vary widely among patients [1].
Although MS is rare, affecting less than 0.1% of the U.S.
population [2], its effects on patient functioning and on
medical service utilization result in high direct and indir-
ect costs, estimated in 1998 to total $2.2 million per U.S.* Correspondence: kathleen@kathleenfairman.com
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reproduction in any medium, provided the orcase per lifetime [3]. Natural history studies conducted
prior to the introduction of disease-modifying drugs
(DMDs) to the market (initially interferon [IFN] beta-1b
in 1993; IFN beta-1a intramuscular [IM] and glatiramer
acetate in 1996) [4] found considerable functional deteri-
oration in the years following disease onset [5]. For ex-
ample, at 10 years post-onset, one-half of patients were
unable to perform daily employment or household activ-
ities; and at 15 years, one-half were unable to walk with-
out assistance [5].
DMD treatment of MS early in the disease course, espe-
cially for patients with relapsing-remitting MS (RRMS)
and to a lesser extent for patients at risk of developingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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care in the United States [4,6]. In 2002, a joint task force
of the American Academy of Neurology and MS Council
for Clinical Practice Guidelines recommended that IFN
beta treatment be considered “in any patient who is at
high risk for developing [CDMS], or who already has ei-
ther RRMS or secondary progressive MS (SPMS) and is
still experiencing relapses” and that treatment with
glatiramer be considered for patients with RRMS [6]. A
2008 disease management consensus statement from the
National Multiple Sclerosis Society indicated that treat-
ment with an IFN beta medication or glatiramer “should
be considered as soon as possible following a definite diag-
nosis of MS with active, relapsing disease, and may also be
considered for selected patients with a first attack who are
at high risk of MS” [7].
Growing consensus about the use of DMDs in MS
treatment has heightened the importance of MS cost-of-
care analyses for health care payers, including employers.
DMDs are high-cost medications, with one economic
analysis estimating total treatment expense including la-
boratory monitoring costs at $2,294 to $2,461 per month
(2008 U.S.$) [8]. However, because both direct medical
care costs and societal costs (e.g., payments for disability
and sick leave, value of caregiver time) increase as the
disease advances [9], the efficacy of DMDs in slowing
the progression of MS has the potential to offset drug
acquisition costs with savings on other resources.
For example, Prescott et al. found that among patients
using a single DMD (monotherapy) in 2004, 75% of total
MS treatment cost was attributable to prescription
drugs, with 73% solely for the DMD [10]. However, they
compared their results with those of a previous cost-of-
care estimate by Pope et al. and concluded that after ac-
counting for inflation, “the cost structure for treating
MS has changed notably”—from a total 1-year cost of
$9,515 with 18% for prescription drugs in 1995, to
$12,879 with 65% for prescription drugs in 2004 [10,11].
Estimating that inflation-adjusted annual medical cost
per patient with MS had declined from $7,802 in 1995
to $4,529 in 2004, Prescott et al. suggested that the
downward shift “may be related to the effectiveness of
DMD therapy in managing MS severity and reducing
functional disability” [10].
In addressing questions about effective treatment ap-
proaches and cost of care, payers commonly turn to pub-
lished observational studies or to pharmacoeconomic
models, which rely on input data to produce information
about expected “real-world” costs and outcomes [12,13].
However, published data about MS treatment costs are
not timely or complete. Early cost estimates by Whetten-
Goldstein et al. and Pope et al. were based on data col-
lected in 1994–1997 [3,11]. The study by Prescott et al.
provided a comprehensive descriptive analysis of thecomponents of MS treatment costs for a large sample but
was based on dates of service in 2004 [10]. Analyses pub-
lished since then have been subject to several common
limitations. Many studied only patients with incident
disease and/or treatment, who might not accurately repre-
sent payers’ cost experiences with prevalent disease popu-
lations [14-19]. All studied patients initiating treatment
prior to 2009 [14-20]. Several excluded DMD costs in
reporting the cost of care [16,18,20]. These inadequacies
in the evidence base are consequential because of im-
portant changes in MS treatment in recent years: the
publication of several new treatment guidelines [21,22];
the withdrawal of natalizumab from the market in February
2005 followed by its reintroduction in June 2006 under a
risk mitigation strategy [23,24]; the approval of a new,
branded IFN beta-1b in August 2009 [25]; and the availabil-
ity of an oral DMD, fingolimod, beginning in September
2010 [4].
To address these gaps in the research literature, the
primary objective of the present study was to support
pharmacoeconomic analyses of MS treatments by pro-
viding an updated assessment of direct health care costs
in a contemporary, prevalent cohort of patients with
MS, replicating the work of Prescott et al. as closely as
possible [10]. The secondary objective, again replicating
the method used by Prescott et al., was to assess the
growth in medical and drug costs over time by compar-
ing aggregated cost data for prevalent samples in 2006
and 2011.
Methods
Design and data source
The study was a retrospective analysis of the i3 Invision™
Data Mart, an integrated database of medical claims, phar-
macy claims, and eligibility data for approximately 14 mil-
lion enrollees of a national health insurance organization.
All enrollees were commercially insured, and most were
located in the southern or midwestern United States.
Available fields on medical claims included International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM) codes for up to 5 diagnoses, as well as
procedure codes (Current Procedural Terminology [CPT],
revenue, and Healthcare Common Procedure Coding
System [HCPCS]). Pharmacy claims fields included drug
brand names, national drug code (NDC) numbers, fill
dates, and days supply. Data were collected as part of nor-
mal business operations and de-identified prior to delivery
to the investigators in accordance with Health Insurance
Portability and Accountability Act (HIPAA) requirements.
Although the study by Prescott et al. used proprietary
Episode Treatment Group (ETG) software to calculate
some study outcomes [10], the present study used only
data elements that are widely available in administrative
claims databases.
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The same sampling process was used to produce MS pa-
tient cohorts for each of the 2 study years, 2006 and
2011. All study patients had (1) at least 1 medical claim
with a diagnosis of MS, defined as either an ICD-9-CM=
340.xx in any diagnosis field or a diagnosis-related group
(DRG) code for MS and cerebellar ataxia (DRG = 058, 059,
or 060) at any time during the study year and (2) continu-
ous eligibility for medical and pharmacy benefits through-
out the study year.
For 2011, a subgroup of patients with at least 1 claim
for a DMD was created. From this subgroup, an additional
subgroup of patients treated with claims for only a single
DMD (monotherapy) was identified. DMDs included IFN
beta-1a subcutaneous (SC), IFN beta-1a IM, IFN beta-1b,
glatiramer acetate, and natalizumab and were identified ei-
ther by brand name on pharmacy claims or HCPCS codes
on medical claims (Table 1).
Analysis
Consistent with the analyses performed by Prescott et al.,
study outcomes reported for 2011 included mean (stand-
ard deviation [SD]) charges for MS services by geographic
region, insurance type, age group, sex, and presence of se-
lected disease sequelae, which were described as comor-
bidities in the report by Prescott et al. MS services were
defined based on a diagnosis of MS (ICD-9-CM or DRG
as described above) in any field on medical claims or re-
ceipt of a DMD as indicated in either medical or phar-
macy claims. Costs were defined as submitted charges
minus any expense that was not covered because of in-
complete information or ineligible services, patients, or
providers. For this reason, we use the term “charge” rather
than “cost” throughout the rest of this report.
To identify disease sequelae, diagnoses in any field were
used. Each condition (abnormality of gait; ataxia; paresthesia
[burning, numbness, or tingling]; convulsions; depression;
fecal incontinence; fibromyalgia/myalgia; malaise and
fatigue; optic neuritis; spasms; trigeminal neuralgia; urin-
ary incontinence; and voice disturbance) was identifiedTable 1 Disease-modifying drugs for multiple sclerosis
Brand Name Generic Name HCPCS Codesa
Avonexb IFN beta-1a IMb J1825, Q3025
Betaseronb, Extavia IFN beta-1b SCb J1830
Copaxoneb Glatiramer acetateb J1595
Gilenya Fingolimod None
Rebifb IFN beta-1a SCb J1826, Q3026
Tysabri Natalizumab J2323, Q4079
aDrugs were identified by brand names on pharmacy claims and HCPCS codes
on medical claims.
bIndicates a DMD included in the study by Prescott et al. [10].
DMD = disease-modifying drug; HCPCS = Healthcare Common Procedure
Coding System; IFN = interferon; IM = intramuscular; SC = subcutaneous.using coding similar to that of Prescott et al., except that:
(1) Prescott et al. used a combination of ICD-9-CM
codes and ETGs to identify disease sequelae, and (2) in the
present study, a DRG of 881 (depressive neuroses) was used
in addition to ICD-9-CM coding to identify depression.
Additional analyses for 2011 included assessments of
MS-related utilization and charges by service category
(inpatient, outpatient emergency room, and DMD) and
separate analyses of DMD monotherapy users by drug.
Although patients treated with fingolimod were included
in the sample overall, they were excluded from the DMD-
specific analyses because of small subgroup size (n = 306).
A final analysis compared the distribution of MS-related
total, medical, and DMD charges for the 2 years, 2006 and
2011, with 2006 charges adjusted to 2011 values using the
medical care component of the Consumer Price Index.
Although the analytic approach was descriptive, inferen-
tial statistical tests, including Pearson chi-square for cat-
egorical variables and t-tests and Analysis of Variance
(ANOVA) for interval- or ratio-scale variables, were used
[10]. No multivariate adjustments were made because the
primary purpose of the study was to provide descriptive
cost data for input into pharmacoeconomic models, not
to assess the cost-effectiveness of the various available
DMDs. Statistical analyses were performed using SAS ver-
sion 9.2 and an a priori significance level of 0.05.
Results
Of potential study subjects with an MS diagnosis or
DRG code during each of the 2 study years (n = 21,112
in 2006 and 20,653 in 2011), more than 70% (n = 15,399
in 2006 and 15,902 in 2011) were continuously eligible
and constituted the MS patient cohort (Figure 1). Of con-
tinuously enrolled patients, the proportions with at least
1 DMD claim were 54% (n = 8,248) in 2006 and 53%
(n = 8,451) in 2011.
The mean (SD) age for the 2011 cohort was 47.6 (11.8)
years, and 76% of study subjects were female (Table 2).
The mean (SD) total MS health care charge in 2011 for
the sample overall was $26,520 ($38,478). MS charges
were slightly but significantly higher for males compared
with females. Charges were distributed in an inverted “U”
shape by age, with the lowest charges for patients younger
than 18 years (< 1% of the sample; mean of $14,142), in-
creasing incrementally to means of $27,430-$27,558 for
those aged 36 to 55 years (57% of the sample), and drop-
ping to a mean of $21,167 among those aged 65 years or
older (5% of the sample).
Charges did not significantly differ by geographic re-
gion but did differ by insurance product type (Table 2).
Among common insurance product types (i.e., not in the
“other” category), mean MS charges ranged from a low of
$22,127 in indemnity plans to a high of $27,933 in exclu-
sive provider organizations.
Figure 1 Sample selection process and cohort identification.
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tients and those without DMD use), inpatient services
made up 12% and DMDs 53% of total MS-related charges
in 2011 (Table 2). Measured by claims volume, the most
commonly used services were outpatient, constituting 62%
of claims and 35% of total MS-related charges.
Subgroup analyses of patients with selected disease se-
quelae indicated that both high- and low-prevalence con-
ditions were associated with substantially increased MS
charges (Table 3). Patients with optic neuritis (n = 38) had
the highest mean charges ($82,134; P = 0.001), followed
by those with abnormality of gait (n = 1,196), spasms
(n = 412), and ataxia (n = 347), with means of $48,337 to
$48,605 (all P < 0.001). Urinary incontinence (n = 339) and
depression (n = 1,255) were also associated with high MS
charges at means of $47,885 and $42,831, respectively
(both P < 0.001). The highest-prevalence sequela was mal-
aise and fatigue, diagnosed in 14.1% of patients (n = 2,235)
and associated with a mean MS charge of $39,948.
For the subgroup of 8,145 patients with at least 1 in-
jectable DMD claim in 2011, the most frequently used
product was glatiramer acetate (40%), followed by IFN
beta-1a IM (22%), IFN beta-1a SC (21%), IFN beta-1b
(11%), and natalizumab (10%; Table 4). Similar DMD use
rates were identified in the subgroup of monotherapy-
treated patients. However, both the mean claims count
and the mean days supply were lower for glatiramer
acetate compared with the other DMDs. A post hoc
follow-up analysis of this finding indicated that the mean
number of days until DMD start, defined as the count of
calendar days from January 1, 2011, through the first DMD
claim date, was greater (P < 0.001) for patients treated with
glatiramer acetate (76.4 days) compared with other DMDs
(41.6 to 54.2 days).Among monotherapy users, the most notable by-
group differences were higher rates of nearly all disease
sequelae for natalizumab-treated patients (Table 4). For
example, the rate of malaise/fatigue was 28% in the nata-
lizumab monotherapy group compared with 12%-17%
for the other DMDs, and abnormality of gait was experi-
enced by 16% in the natalizumab group compared with
6%-10% in the other groups. Natalizumab-treated patients
also experienced higher rates of ataxia, paresthesia, depres-
sion, fibromyalgia/myositis, spasms, and urinary incontin-
ence. Patients treated with natalizumab monotherapy had
the highest mean total MS charges ($81,627), followed
by patients treated with IFN beta-1b ($48,529), IFN beta-
1a IM and SC ($45,770-$45,928), and glatiramer acetate
($38,509; Table 4). Service categories with significant by-
group differences included outpatient (mean $23,702 for
natalizumab versus $6,485-$7,931 for the remaining DMDs)
and DMD ($54,255 for natalizumab versus $27,694-$37,498
for the remaining DMDs). DMDs accounted for 75% of
total MS-related charges overall, ranging from a low of 67%
for natalizumab to a high of 81% for IFN beta-1a IM.
In the sample overall from 2006 to 2011, total mean
MS charges per patient after adjustment for medical cost
inflation increased by 60%, from $16,614 to $26,520
(Table 5). Medical charges rose at a lower rate (33%)
than did DMD charges (96%). Expressed as a proportion
of the total, medical charges declined from 57% in 2006
to 47% in 2011.
Discussion
The present study sought to replicate and update a pre-
viously published, comprehensive assessment of MS-
related health care costs using a retrospective analysis of
a large database of commercially insured patients. The
Table 2 MS chargesa in 2011
N % of Total Mean [SD] charge per patient ($) P Value
All patients 15,902 100.0 26,520 [38,478]
By patient characteristics
Gender <0.001b
Female 12,100 76.1 26,224 [38,716]
Male 3,801 23.9 27,445 [37,691]
Unknown 1 0.0 90,704 [NA]
Age in years <0.001
17 or younger 126 0.8 14,142 [40,310]
18 to 25 405 2.6 25,731 [44,296]
26 to 35 2,009 12.6 26,324 [36,224]
36 to 45 4,021 25.3 27,430 [36,866]
46 to 55 5,030 31.6 27,558 [39,653]
56 to 64 3,499 22.0 25,876 [38,022]
65 or older 812 5.1 21,167 [42,005]
Region
Northeast 1,861 11.7 27,035 [38,558] 0.646
Midwest 4,480 28.2 25,820 [32,754]
South 6,730 42.3 26,604 [40,196]
West 2,827 17.8 27,093 [42,457]
Other 4 0.0 23,745 [28,601]
Insurance product 0.032
EPO 2,088 13.1 27,933 [42,360]
HMO 1,474 9.3 24,628 [33,046]
Indemnity 329 2.1 22,127 [39,181]
POS 11,336 71.3 26,648 [38,173]
PPO 641 4.0 26,622 [41,918]
Other 34 0.2 19,353 [28,310]
Charge components Utilizationc
Mean [SD]
Mean [SD] Cost ($) % of Total Cost
Inpatientd 0.48 [2.75] 3,179 [17,860] 12.0
Outpatientd 6.05 [8.04] 9,355 [24,523] 35.3
Emergency Roomd 0.03 [0.39] 33 [522] 0.1
DMD 3.17 [4.87] 13,953 [21,704] 52.6
aSum of the charges for (1) medical claims with an MS diagnosis (ICD-9-CM= 340.xx in any diagnosis field or a DRG code for MS and cerebellar ataxia [DRG = 058, 059,
or 060]) plus (2) medical or pharmacy claims indicating a DMD (Table 1).
bExcluding the patient with unknown gender (i.e., t-test for female versus male).
cNumber of claims. Claims counts for DMDs include both medical and pharmacy claims.
dCharges for medical claims with an MS diagnosis (ICD-9-CM = 340.xx in any diagnosis field or a DRG code for MS and cerebellar ataxia [DRG = 058, 059, or 060]).
DMD = disease-modifying drug; DRG = Diagnosis-Related Group; EPO = exclusive provider organization; HMO = health maintenance organization; MS =multiple
sclerosis; NA = not applicable; POS = point of service; PPO = preferred provider organization; SD = standard deviation.
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in a 2013 comprehensive economic review of MS treat-
ment cost-effectiveness as “sorely needed” because of
“advances during the last decade in the care and treatment
of MS” [26]. Because pharmacoeconomic models consti-
tute the vast bulk of the literature on MS treatment cost-
effectiveness (32 of the 37 studies included in the 2013review), results of descriptive cost analyses can be, and
often are, used as model input values that should be regu-
larly updated as new information becomes available [27].
The study sample was drawn from a large, frequently
used, national database of insurance claims and was demo-
graphically similar to that of Prescott et al., with a mean
age of 47.6 years and percentage female of 76%, compared
Table 3 MS chargesa by presence of selected disease sequelae in 2011
Condition Diagnosis codeb N Prevalence Mean [SD] charges ($) P Value
Abnormality of gait 781.2 1,196 7.5 48,361 [55,472] <0.001
Ataxia 781.3 347 2.2 48,605 [63,100] <0.001
Burning, numbness, tingling sensations 782.0 1,566 9.8 33,648 [45,273] <0.001
Convulsionsc 780.3 0 0.0 — —
Depressiond 296.2, 296.3, 300.4, 311; DRG = 881 1,255 7.9 42,831 [51,693] <0.001
Fecal incontinence 787.6 0 0.0 — —
Fibromyalgia/myalgia and myositis 729.1 399 2.5 38,319 [63,441] <0.001
Malaise and fatiguec 780.7 2,235 14.1 39,948 [48,435] <0.001
Optic neuritis 341.0 38 0.2 82,134 [98,886] 0.001
Spasms 781.0 412 2.6 48,337 [52,475] <0.001
Trigeminal neuralgia 350.1 150 0.9 38,165 [46,506] 0.002
Urinary incontinencec 788.3 339 2.1 47,885 [49,226] <0.001
Voice disturbancec 784.4, 784.5 23 0.1 44,973 [57,858] 0.140
aSum of the charges for (1) medical claims with an MS diagnosis (ICD-9-CM = 340.xx in any diagnosis field or a DRG code for MS and cerebellar ataxia [DRG = 058, 059,
or 060]) plus (2) medical or pharmacy claims indicating a DMD (Table 1).
bICD-9-CM coding except where otherwise specified.
cIdentified by Prescott et al. using a combination of ICD-9-CM codes and ETG coding [10].
dIdentified by Prescott et al. using only ETG coding [10].
DMD = disease-modifying drug; DRG = Diagnosis-Related Group; ETG = Episode Treatment Group; ICD-9-CM = International Classification of Diseases, Ninth Revision,
Clinical Modification; MS =multiple sclerosis; SD = standard deviation.
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sample. Results of the present study indicated that total
inflation-adjusted MS health care charges increased by
60% from 2006 to 2011 and pointed to a number of im-
portant cost drivers.
Foremost, like Prescott et al., we found that common
disease sequelae are associated with substantially higher
charges for MS-related health care [10]. In both studies,
optic neuritis was associated with a charge of more than
200% above average but was rare, affecting 0.4% of the
Prescott et al. sample and 0.2% of the present study sam-
ple. Abnormality of gait was experienced by 7.4%-7.5%
of the patients in both samples; it was associated with
charges of 62% and 82% above average in the Prescott
et al. study and the present study, respectively.
Malaise and fatigue, depression, and paresthesia were
the highest-prevalence disease sequelae in both studies
[10]. However, in the present study compared with the
study by Prescott et al., these conditions were lower in
prevalence (8%-14% vs. 17%-22%, respectively) and asso-
ciated with greater charge increases (27%-62% above
average in the present study vs. no significant difference
for paresthesia and charge increases of 8%-13% for de-
pression and malaise/fatigue in the study by Prescott
et al.). These variations may be partly due to methodo-
logical differences. Specifically, the present study used
diagnosis and DRG codes to identify disease sequelae
and to calculate MS-related charges, whereas the study
by Prescott et al. used the ETG methodology. However,
it is possible that changes in MS treatment practices,including the promulgation of several guidelines since
2004, have resulted in changes in the reporting, preva-
lence, and/or cost of disease sequelae.
The present study found an inverted U-shaped distri-
bution of charges by age, peaking at the ages of 36 to
55 years and dropping among patients aged 65 years or
older. This result is similar to that obtained by Prescott
et al., although as expected, charges were lower in 2004
than in 2011. Prescott et al. found mean 1-year MS-
related charges of $4,464 for those younger than 18 years,
$13,130-$13,525 for those aged 36 to 55 years, and
$9,677 for those aged 65 years or older.
Unlike Prescott et al., we did not find a decline in
medical charges when we examined change over time,
although we did find that medical charges increased at a
lower rate of growth than did DMD charges in the sam-
ple overall, including both DMD users and patients not
treated with DMDs. Nonetheless, among DMD mono-
therapy users in 2011, DMD charges were responsible
for 75% of treatment costs, similar to the proportion re-
ported by Prescott et al. (73%) for patients treated with
DMD monotherapy in 2004 [10].
The increase in DMD charges from 2006 to 2011 in
the sample overall may be attributable to an increased
number of available DMDs, as well as price inflation
among existing DMDs [28]. A surprising finding of the
present study is that the proportion of continuously en-
rolled patients with at least 1 DMD claim remained con-
stant at about 53%-54% from 2006 to 2011. Also surprising
is that the DMD use rate estimated in the present study is
Table 4 DMD utilization and patient characteristics: patients with MS in 2011
IFN beta-1a IM IFN beta-1b Glatiramer acetate IFN beta-1a SC Natalizumab Total
All DMD users—n (%)a 1,827 (22.4) 902 (11.1) 3,261 (40.0) 1,725 (21.1) 800 (9.8) 8,145
DMD monotherapy
users—n (%)
1,718 (22.0) 842 (10.8) 3,029 (38.8) 1,544 (19.8) 672 (8.6) 7,805
Characteristics of DMD monotherapy users in 2011
IFN beta-1a IM IFN beta-1b Glatiramer acetate IFN beta-1a SC Natalizumab P value
Demographics
Gender n (%)b,c 0.002
Female 1,313 (76.4) 622 (73.9) 2,354 (77.7) 1,122 (72.7) 501 (74.6)
Male 404 (23.5) 220 (26.1) 675 (22.3) 422 (27.3) 171 (25.4)
Mean [SD] ageb 49.6 [10.1] 47.5 [11.1] 47.3 [11.0] 45.2 [10.5] 45.6 [10.1] < 0.001
Mean [SD] DMD claimsb,d 9.21 [4.34] 9.09 [3.91] 5.95 [4.14] 9.03 [4.10] 8.92 [3.98] < 0.001
Mean [SD] days supplyb,d 274.6 [93.4] 265.3 [95.5] 186.3 [122.3] 260.9 [105.2] 241.3 [107.8] < 0.001
Mean [SD] days until
DMD startb,d
45.80 [67.49] 41.57 [62.24] 76.43 [93.28] 54.17 [77.80] 49.05 [74.87] < 0.001
Disease sequelaeb
Abnormality of gait 104 (6.1) 80 (9.5) 247 (8.2) 133 (8.6) 107 (15.9) < 0.001
Ataxia 20 (1.2) 26 (3.1) 68 (2.2) 37 (2.4) 29 (4.3) < 0.001
Burning, numbness,
tingling sensations
160 (9.3) 80 (9.5) 305 (10.1) 174 (11.3) 94 (14.0) 0.008
Convulsions 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Depression 125 (7.3) 74 (8.8) 279 (9.2) 143 (9.3) 90 (13.4) < 0.001
Fecal incontinence 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Fibromyalgia/myalgia
and myositis
26 (1.5) 15 (1.8) 84 (2.8) 27 (1.7) 24 (3.6) 0.003
Malaise and fatigue 209 (12.2) 137 (16.3) 493 (16.3) 261 (16.9) 187 (27.8) < 0.001
Optic neuritis 2 (0.1) 2 (0.2) 4 (0.1) 2 (0.1) 2 (0.3) 0.809
Spasms 33 (1.9) 23 (2.7) 73 (2.4) 39 (2.5) 37 (5.5) < 0.001
Trigeminal neuralgia 14 (0.8) 5 (0.6) 30 (1.0) 15 (1.0) 9 (1.3) 0.621
Urinary incontinence 31 (0.2) 21 (0.2) 61 (2.0) 23 (1.5) 29 (4.3) < 0.001
Voice disturbance 4 (0.2) 0 (0.0) 6 (0.2) 1 (0.1) 2 (0.3) 0.449


































































aCounts (%) sum to more than the total DMD user cohort size (100%) because patients could be treated with more than 1 DMD during the year.
bCalculated for patients using a single DMD during 2011 (n = 7,805).
cTable and chi-square test exclude 1 patient treated with IFN beta-1a with missing gender information.
dIncludes both medical and pharmacy claims. Days until DMD start represents the number of days from January 1, 2011, until the date of the first DMD claim. For
medical claims, days supply was estimated based on the expected dosing schedule for each DMD (count of injections × interval based on dosing schedule).
eCharges for medical claims with an MS diagnosis (ICD-9-CM = 340.xx in any diagnosis field or a DRG code for MS).
DMD = disease-modifying drug; IFN = interferon; IM = intramuscular; MS =multiple sclerosis; SC = subcutaneous; SD = standard deviation.
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Table 5 Comparison of MS charges for 2006 and 2011
Study year and cohort Service component
Medical DMD Total
2006 (n = 15,399)
Charges ($) 7,966 5,989 13,955
Adjusted charges ($)a 9,484 7,130 16,614
Percentage of total charges 57.1% 42.9%
2011 (n = 15,902)
Charges ($) 12,567 13,953 26,520
Percentage of total charges 47.4% 52.6%
Percentage change from
adjusted 2006 to 2011
32.5% 95.7% 59.6%
aAdjusted for the medical component of the Consumer Price Index.
DMD = disease-modifying drug; MS =multiple sclerosis.
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http://www.biomedcentral.com/1472-6963/14/286less than the 58% reported by Prescott et al. for patients
treated in 2004 [10]. It is possible that physicians have
either maintained or slightly declined their rate of adop-
tion of DMDs. It is also possible that the diagnosed
population has changed over time to include a greater
proportion of patients with forms of MS not FDA-
approved for treatment with DMDs, such as nonre-
lapsing MS. ICD-9-CM coding does not distinguish
between types of MS and therefore cannot be used to
provide an answer to that question.
The addition of natalizumab to the treatment arma-
mentarium in 2006 likely contributed to higher charges
for both pharmacy and medical services in the present
study. In the analysis of the DMD monotherapy cohort,
patients treated with natalizumab incurred the highest
MS charges, especially in the outpatient service category.
This difference may be partly due to higher rates of
disease sequelae associated with greater disease sever-
ity, because the Risk Evaluation and Mitigation Strategy
(REMS) program under which natalizumab is made avail-
able calls for its use only as a second-line drug [24,29,30].
Greater resource utilization for patients treated with
natalizumab may also result from REMS program re-
quirements for a schedule of outpatient monitoring and
magnetic resonance imaging scan prior to the start of
treatment [24,29,30].
Limitations
The foremost limitations of the present study arise from
methodological uncertainty in replicating a study based
on a proprietary methodology. Patients in the analysis by
Prescott et al. were required to have both a diagnosis of
MS and an ETG indicating central nervous system in-
flammation, and ETG codes were used to capture MS-
related charges [10]. Additionally, the database used by
Prescott et al. included publicly funded health plans
(i.e., Medicare, Medicaid), whereas the current studydatabase was limited to commercially insured patients.
Despite these limitations, the age distributions of the sam-
ples were similar, and both studies identified similar lists
of disease sequelae as cost drivers.
Second, the present study, like that of Prescott et al.,
was limited to direct health care charges, although indirect
costs due to MS are substantial and increase at higher dis-
ease severity levels [9]. Additionally, the study’s results are
based on U.S. patients and may not generalize to other
countries; a systematic review by Naci et al. (2010) found
that “cost drivers varied across geographies likely due to
the significant differences in the availability of services and
resource use patterns across countries” [9]. Finally, be-
cause all study patients were continuously enrolled, results
cannot be used to draw conclusions about mortality re-
lated to MS.
Third, the present study’s finding of lower claims
counts and days supply for glatiramer acetate than for
the other DMDs among monotherapy users was related
to a later start date in calendar year 2011—averages of
76 days (March 18) versus 42 to 54 days (February 12 to
February 24), respectively. This finding, which is not
consistent with the results of Prescott et al., may be due
to plan formulary or benefit design requirements that are
not visible within the study database. However, there is no
reason to believe that it had a substantial effect on key
study results. For example, excluding patients treated with
glatiramer acetate, the proportion of total MS cost at-
tributable to DMDs is 76%, similar to the 75% for DMD
monotherapy-treated patients overall.
Fourth, although DMD monotherapy users in 2006
might have provided a better point of comparison than
the sample of Prescott et al. for the analysis of change in
DMD proportional cost over time, use of this subsample
was not possible for the 2006 cohort because of difficulties
in obtaining detailed cost data. The analysis of 2006 was
limited to a secondary objective of the present study.
Fifth, because of its 12-month follow-up time, the
present study did not meet the need for longitudinal co-
hort data for patients with MS [26]. To provide informa-
tion about the potential cost implications of natural
disease history changes due to DMD use, cohort studies
with a longer follow-up time are an important area for
future research.
Conclusion
Over a 5-year period from 2006 to 2011, total inflation-
adjusted, MS-related charges increased by 60%. MS-
related costs among patients treated with different DMDs
ranged from 1-year means of $38,509 to $81,627. For
DMD monotherapy users, 75% of total MS-related health
care cost in 2011 was for DMDs, similar to the percentage
previously reported for patients treated in 2004. Sequalae
of MS contributed significantly to the total cost of care.
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